- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Apex Today
By the People, for the People
Foxx Development CTO Sells Over 9,700 Shares
Insider transaction raises questions about the company's future direction.
Mar. 11, 2026 at 2:26am
Got story updates? Submit your updates here. ›
Foxx Development Holdings Inc. (NASDAQ:FOXX) CTO James Liao sold 9,716 shares of the company's stock in a transaction on February 19th. The shares were sold at an average price of $4.61, resulting in a total transaction value of $44,790.76.
Why it matters
Insider selling can sometimes signal concerns about a company's prospects, though the reasons behind the transaction are not always clear. As a key executive, the CTO's sale of a sizable number of shares may raise questions about Foxx Development's future direction among investors.
The details
According to a legal filing with the SEC, CTO James Liao sold 9,716 shares of Foxx Development stock on February 19th. The shares were sold at an average price of $4.61, resulting in a total transaction value of $44,790.76. Foxx Development is a contract manufacturer specializing in medical devices and components, with a focus on phlebotomy and blood collection products.
- The insider transaction occurred on February 19, 2026.
The players
James Liao
The Chief Technology Officer (CTO) of Foxx Development Holdings Inc.
Foxx Development Holdings Inc.
A NASDAQ-listed contract manufacturer specializing in the design, assembly and distribution of medical devices and components, with a focus on phlebotomy and blood collection products.
The takeaway
The CTO's sale of a sizable number of Foxx Development shares raises questions about the company's future direction, though the specific reasons behind the transaction are not clear. Investors will likely be closely monitoring the company's performance and any further insider trading activity.


